PARATHYROID HORMONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125511s000lbl.pdf / https://www.ncbi.nlm.nih.gov/pubmed/28676438

Parathyroid hormone (PTH) is an 84-amino acid peptide that regulates the function of osteoblasts and osteocytes and is secreted by the parathyroid gland in response to changes in the concentration of extracellular calcium. Parathyroid hormone is approved under the brand name NATPARA as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. It is also available for treatment of postmenopausal osteoporosis in many European countries. Parathyroid hormone is an activator of parathyroid hormone 2 receptor. In addition, was shown, that downregulation of Notch in osteoblasts and osteocytes may represent a mechanism contributing to the anabolic effects of parathyroid hormone in bone.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Parathyroid hormone 2 receptor 1 Target ID: P49190 Gene ID: 5746.0 Gene Symbol: PTH2R Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7797535	Agonist 2678
Notch signaling pathway 2 Target ID: map04330 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28676438	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypoparathyroidism 5 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125511s000lbl.pdf	Palliative		Approved 8429	NATPARA Approved Use NATPARA is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Because of the potential risk of osteosarcoma, NATPARA is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations. NATPARA was not studied in patients with acute post-surgical hypoparathyroidism. Launch Date 2015
Postmenopausal osteoporosis 59 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23500550	Palliative		Approved 8429	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis.	2012 Mar	22256908
The effect of parathyroid hormone and teriparatide on fracture healing.	2015 Jan	25363308

Patents

Sample Use Guides

In Vivo Use Guide

Initiate NATPARA ((parathyroid hormone) 50 mcg once daily as a subcutaneous njection in the thigh (alternate thigh very day). n patients using active forms of vitamine D decrease the dose of active vitamin D by 50%, if serum calcium is above 7.5 mg/dL. In patients using calcium supplements, maintain calcium supplement dose. Measure serum calcium concentration within 3 to 7 days.

Route of Administration: Other

In Vitro Use Guide

Unknown

Name

Type

Language

PARATHYROID HORMONE

Official Name

English

parathyroid hormone [INN]

Common Name

English

NATPAR

Brand Name

English

PREOTACT

Brand Name

English

PARATHYROID [HSDB]

Common Name

English

ALX-1-11

Code

English

NATPARA

Brand Name

English

Parathyroid hormone [WHO-DD]

Common Name

English

PTH

Common Name

English

PARATHYROID HORMONE [PURPLE BOOK CDER]

Common Name

English

PARATHORMONUM [HPUS]

Common Name

English

PARATHYROID HORMONE [USAN]

Common Name

English

PARATHYROID HORMONE (RDNA)

Common Name

English

PARATHORMONE (HUMAN RECOMBINANT)

Common Name

English

PARATHYROID HORMONE [MI]

Common Name

English

PARATHYROID HORMONE (RDNA) [EMA EPAR]

Common Name

English

rhPTH(1-84)

Common Name

English

PARATHORMONUM

Common Name

English

PARATHYROID HORMONE [MART.]

Common Name

English

Classification Tree Code System Code

EU-Orphan Drug

EU/3/13/1210